Sedana Medical publishes Annual Report 2021
Sedana Medical AB (publ) (SEDANA: FN Stockholm) published its Annual Report 2021.
In addition to significant events and financial information of 2021, the Annual Report focuses on the strategic priorities and ambitions to introduce inhaled sedation to intensive care.
“In 2021, we delivered the highest turnover in our history and made strong progress on both of our main priorities: to execute an excellent launch of Sedaconda (isoflurane) in Europe and to prepare for the important US market”, said Johannes Doll, CEO of Sedana Medical.
The Annual Report is available at www.sedanamedical.com.
For additional information, please contact:
Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on April 7, 2022, at 15:00 am (CET).
Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, email@example.com.
About Sedana Medical
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.